Endocrine Tumor Board
Haugen BR, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016 Jan;26(1):1-133.
Francis GL, et al; American Thyroid Association Guidelines Task Force. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2015 Jul;25(7):716-59.
Genitourinary/Urology Tumor Board
Kitajima K, et al. FDG-PET/CT as a post-treatment restaging tool in urothelial carcinoma: Comparison with contrast-enhanced CT. Eur J Radiol. 2016 Mar;85(3):593-8.
Hofman MS, et al. Prostate-specific Membrane Antigen PET: Clinical Utility in Prostate Cancer, Normal Patterns, Pearls, and Pitfalls. Radiographics. 2018 Jan-Feb;38(1):200-217.
Gusman M, et al. Review of 18F-Fluciclovine PET for Detection of Recurrent Prostate Cancer. Radiographics. 2019 May-Jun;39(3):822-841.
Barbosa FG, et al. Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread. Radiographics. 2019 Jan-Feb;39(1):186-212.
Zattoni F, et al. 18F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study. Cancers (Basel). 2019 May 20;11(5):700.
Zukotynski K, Lewis A, O'Regan K, Jacene H, Sakellis C, Krajewski K, Israel D. PET/CT and renal pathology: a blind spot for radiologists? Part 1, primary pathology. AJR Am J Roentgenol. 2012 Aug;199(2):W163-7.
Kandathil A, et al. Metabolic and anatomic characteristics of benign and malignant adrenal masses on positron emission tomography/computed tomography: a review of literature. Endocrine. 2015 May;49(1):6-26.
Head and Neck / ENT / OTO Tumor Board
Steuer CE, El-Deiry M, Parks JR, Higgins KA, Saba NF. An update on larynx cancer. CA Cancer J Clin. 2017 Jan;67(1):31-50.
Hoang JK, Vanka J, Ludwig BJ, Glastonbury CM. Evaluation of cervical lymph nodes in head and neck cancer with CT and MRI: tips, traps, and a systematic approach. AJR Am J Roentgenol. 2013 Jan;200(1):W17-25.
Joshi VM, Wadhwa V, Mukherji SK. Imaging in laryngeal cancers. Indian J Radiol Imaging. 2012 Jul;22(3):209-26.
Spector JG, Sessions DG, Haughey BH, Chao KS, Simpson J, El Mofty S, Perez CA. Delayed regional metastases, distant metastases, and second primary malignancies in squamous cell carcinomas of the larynx and hypopharynx. Laryngoscope. 2001 Jun;111(6):1079-87.
Melanoma Tumor Board
Perng P, Marcus C, Subramaniam RM. (18)F-FDG PET/CT and Melanoma: Staging, Immune Modulation and Mutation-Targeted Therapy Assessment, and Prognosis. AJR Am J Roentgenol. 2015 Aug;205(2):259-70.
Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z. Imaging-based Biomarkers for Predicting and Evaluating Cancer Immunotherapy Response. Radiol Imaging Cancer. 2019 Nov 29;1(2):e190031.
Lee EJ, Chung HW, Jo JH, So Y. Radioembolization for the Treatment of Primary and Metastatic Liver Cancers. Nucl Med Mol Imaging. 2019 Dec;53(6):367-373. doi: 10.1007/s13139-019-00615-9.
Myeloma Tumor Board
Mesguich C, et al. State of the art imaging of multiple myeloma: comparative review of FDG PET/CT imaging in various clinical settings. Eur J Radiol. 2014 Dec;83(12):2203-2223.
Jamet B, et al. Imaging of Monoclonal Gammapathy of Undetermined Significance and Smoldering Multiple Myeloma. Cancers (Basel). 2020 Feb 19;12(2):486.
Kousgaard SJ, et al. Incidental detection of colorectal lesions on 18 F-FDG-PET/CT is associated with high proportion of malignancy: A study in 549 patients. Endosc Int Open. 2020 Dec;8(12):E1725-E1731.
Agarwal A, Chirindel A, Shah BA, Subramaniam RM. Evolving role of FDG PET/CT in multiple myeloma imaging and management. AJR Am J Roentgenol. 2013 Apr;200(4):884-90.
PRRT Tumor Board
Burkett BJ, et al. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology. 2021 Feb;298(2):261-274.
Bellizzi AM. Pathologic Considerations in Gastroenteropancreatic Neuroendocrine Tumors. Surg Oncol Clin N Am. 2020 Apr;29(2):185-208.
Hope TA, Bergsland EK, Bozkurt MF, et al. Appropriate Use Criteria for Somatostatin Receptor PET Imaging in Neuroendocrine Tumors. J Nucl Med. 2018;59(1):66-74. doi:10.2967/jnumed.117.202275
Pencharz D, Gnanasegaran G, Navalkissoor S. Theranostics in neuroendocrine tumours: somatostatin receptor imaging and therapy. Br J Radiol. 2018;91(1091):20180108.
Thoracic Tumor Board
Kandathil A, et al. Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. Radiographics. 2018 Nov-Dec;38(7):2134-2149.
Detterbeck FC. Multifocal adenocarcinoma: perspectives, assumptions and elephants. J Thorac Dis. 2018 Mar;10(3):1193-1197.
Sheard S, et al. Lung Cancers Associated with Cystic Airspaces: Underrecognized Features of Early Disease. Radiographics. 2018 May-Jun;38(3):704-717.
Jiang Y, et al. The utility of 18F-FDG and 68Ga-DOTA-Peptide PET/CT in the evaluation of primary pulmonary carcinoid: A systematic review and meta-analysis. Medicine (Baltimore). 2019 Mar;98(10):e14769.
Larici AR, et al. Lung abnormalities at multimodality imaging after radiation therapy for non-small cell lung cancer. Radiographics. 2011 May-Jun;31(3):771-89.
Kim TJ, et al. Multimodality assessment of esophageal cancer: preoperative staging and monitoring of response to therapy. Radiographics. 2009 Mar-Apr;29(2):403-21.
Hong SJ, et al. New TNM staging system for esophageal cancer: what chest radiologists need to know. Radiographics. 2014 Oct;34(6):1722-40.
Nasseri F, Eftekhari F. Clinical and radiologic review of the normal and abnormal thymus: pearls and pitfalls. Radiographics. 2010 Mar;30(2):413-28.
Tumor board contact: email@example.com
NCCN - Notes: Set up a free account to the NCCN comprehensive cancer care guidelines. These will help you understand the role radiology and nuclear medicine play in the staging, re-staging, and management of cancer patients.